Allspring Global Investments Holdings LLC Decreases Holdings in Stevanato Group S.p.A. (NYSE:STVN)

Allspring Global Investments Holdings LLC cut its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 1.8% during the 1st quarter, HoldingsChannel reports. The fund owned 102,594 shares of the company’s stock after selling 1,843 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Stevanato Group were worth $3,293,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. PNC Financial Services Group Inc. grew its holdings in shares of Stevanato Group by 54.2% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,089 shares of the company’s stock worth $84,000 after purchasing an additional 1,086 shares during the last quarter. Wellington Management Group LLP increased its position in Stevanato Group by 8.3% during the 4th quarter. Wellington Management Group LLP now owns 583,875 shares of the company’s stock valued at $15,934,000 after purchasing an additional 44,700 shares during the period. First Light Asset Management LLC raised its holdings in Stevanato Group by 24.8% in the 4th quarter. First Light Asset Management LLC now owns 729,961 shares of the company’s stock worth $19,921,000 after purchasing an additional 145,206 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new stake in shares of Stevanato Group in the 4th quarter worth about $3,076,000. Finally, Personal CFO Solutions LLC boosted its stake in shares of Stevanato Group by 4.6% during the 4th quarter. Personal CFO Solutions LLC now owns 12,186 shares of the company’s stock valued at $333,000 after purchasing an additional 534 shares in the last quarter.

Stevanato Group Price Performance

Stevanato Group stock traded down €0.28 ($0.30) during mid-day trading on Tuesday, reaching €18.45 ($19.84). 44,658 shares of the stock traded hands, compared to its average volume of 479,629. The company has a quick ratio of 1.35, a current ratio of 1.92 and a debt-to-equity ratio of 0.21. Stevanato Group S.p.A. has a 12-month low of €16.56 ($17.81) and a 12-month high of €36.30 ($39.03). The business’s 50-day moving average is €21.12 and its 200-day moving average is €26.78.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings data on Thursday, May 9th. The company reported €0.09 ($0.10) EPS for the quarter, missing analysts’ consensus estimates of €0.12 ($0.13) by (€0.03) (($0.03)). The firm had revenue of €256.24 million for the quarter, compared to analysts’ expectations of €261.28 million. Stevanato Group had a net margin of 12.57% and a return on equity of 12.61%. Equities research analysts anticipate that Stevanato Group S.p.A. will post 0.54 earnings per share for the current year.

Stevanato Group Announces Dividend

The business also recently declared an annual dividend, which will be paid on Monday, July 15th. Shareholders of record on Tuesday, June 4th will be given a $0.053 dividend. This represents a yield of 0.29%. The ex-dividend date of this dividend is Tuesday, June 4th.

Analyst Ratings Changes

STVN has been the subject of several research analyst reports. Stephens restated an “overweight” rating and issued a $38.00 price objective on shares of Stevanato Group in a report on Monday, March 25th. Morgan Stanley restated an “equal weight” rating and set a $30.00 price target on shares of Stevanato Group in a research report on Monday, April 22nd. Finally, BNP Paribas assumed coverage on Stevanato Group in a research report on Monday, April 22nd. They set an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of €34.17 ($36.74).

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.